# Biomarkers in Predicting Response to Treatment in Patients With Newly Diagnosed Stage III or Stage IV Head and Neck Cancer Treated With Carboplatin, Paclitaxel, and Radiation Therapy

> **NCT00898430** · — · TERMINATED · sponsor: **Vanderbilt-Ingram Cancer Center** · enrollment: 49 (actual)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **GENETIC:** DNA Microarray analysis
- **GENETIC:** MALDI-TOF mass spectrometry
- **GENETIC:** DNA microarray and MALDI-TOF mass spectrometry

## Key facts

- **NCT ID:** NCT00898430
- **Lead sponsor:** Vanderbilt-Ingram Cancer Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2003-11
- **Primary completion:** 2011-02
- **Final completion:** 2011-02
- **Target enrollment:** 49 (ACTUAL)
- **Why stopped:** Study closed prematurely upon PI's departure
- **Last updated:** 2013-04-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00898430

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00898430, "Biomarkers in Predicting Response to Treatment in Patients With Newly Diagnosed Stage III or Stage IV Head and Neck Cancer Treated With Carboplatin, Paclitaxel, and Radiation Therapy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00898430. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*